Experienced in Septo-Optic Dysplasia

Dr. Steven M. Willi

Pediatric Endocrinology | Pediatrics
3401 Civic Center Blvd, Childen's Hospital Of Philadelphia - Endocrinology, 
Philadelphia, PA 
Experienced in Septo-Optic Dysplasia
3401 Civic Center Blvd, Childen's Hospital Of Philadelphia - Endocrinology, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Steven Willi is a Pediatric Endocrinologist and a Pediatrics provider in Philadelphia, Pennsylvania. Dr. Willi is rated as an Experienced provider by MediFind in the treatment of Septo-Optic Dysplasia. His top areas of expertise are Type 1 Diabetes (T1D), Congenital Hyperinsulinism, Type 2 Diabetes (T2D), and Obesity in Children.

His clinical research consists of co-authoring 78 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pediatric Endocrinology
Pediatrics
Licenses
Pediatrics in PA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Avalon Health Care
  • MEDICARE PDP
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
View 12 Less Insurance Carriers -

Locations

3401 Civic Center Blvd, Childen's Hospital Of Philadelphia - Endocrinology, Philadelphia, PA 19104

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With an Open-Label Extension Assessing the Efficacy, Safety, and Pharmacokinetics/Pharmacodynamics of Tirzepatide in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, or Basal Insulin, or Both
Enrollment Status: Completed
Publish Date: September 26, 2025
Intervention Type: Drug
Study Drug: Tirzepatide
Study Phase: Phase 3
INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric Subjects With Type 1 or Type 2 Diabetes Mellitus
INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric Subjects With Type 1 or Type 2 Diabetes Mellitus
Enrollment Status: Completed
Publish Date: May 06, 2025
Intervention Type: Biological
Study Drugs: Afrezza, Rapid-acting Insulin Analog, Basal Insulin
Study Phase: Phase 3
An Open-Label, Multi-Center, Single-Dose Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Nasal Glucagon in Pediatric Patients With Type 1 Diabetes Aged 1 to <4 Years
An Open-Label, Multi-Center, Single-Dose Study to Assess the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Nasal Glucagon in Pediatric Patients With Type 1 Diabetes Aged 1 to <4 Years
Enrollment Status: Completed
Publish Date: May 23, 2024
Intervention Type: Drug
Study Drug: Glucagon
Study Phase: Phase 1
A Randomized, Double-Blind Study With an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (AWARD-PEDS: Assessment of Weekly AdministRation of LY2189265 in Diabetes-PEDiatric Study)
A Randomized, Double-Blind Study With an Open-Label Extension Comparing the Effect of Once-Weekly Dulaglutide With Placebo in Pediatric Patients With Type 2 Diabetes Mellitus (AWARD-PEDS: Assessment of Weekly AdministRation of LY2189265 in Diabetes-PEDiatric Study)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drug: Dulaglutide
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog With an Open-Label Postprandial LY900014 Treatment Group in Children and Adolescents With Type 1 Diabetes
Enrollment Status: Completed
Publish Date: January 24, 2022
Intervention Type: Drug
Study Drugs: LY900014, Insulin Lispro
Study Phase: Phase 3
Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI)
Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI)
Enrollment Status: Completed
Publish Date: September 08, 2021
Intervention Type: Drug, Other
Study Phase: Phase 2
View 5 Less Clinical Trials

78 Total Publications

Building an Infrastructure to Address Racial Disparities in Treatment and Outcomes in Children with Type 1 Diabetes.
Building an Infrastructure to Address Racial Disparities in Treatment and Outcomes in Children with Type 1 Diabetes.
Journal: Endocrinology and metabolism clinics of North America
Published: May 10, 2025
Similar Doctors
Advanced in Septo-Optic Dysplasia
Dr. Aditi Khokhar
Pediatric Endocrinology
Advanced in Septo-Optic Dysplasia
Dr. Aditi Khokhar
Pediatric Endocrinology
194 Route 31, 
Flemington, NJ 
 (44.1 miles away)
973-971-4340
Languages Spoken:
English
See accepted insurances

Aditi Khokhar is a Pediatric Endocrinologist in Flemington, New Jersey. Dr. Khokhar is rated as an Advanced provider by MediFind in the treatment of Septo-Optic Dysplasia. Her top areas of expertise are Dyggve-Melchior-Clausen Syndrome, Precocious Puberty, Septo-Optic Dysplasia, and Obesity in Children.

Advanced in Septo-Optic Dysplasia
Dr. Rita Ann Kubicky
Pediatric Endocrinology
Advanced in Septo-Optic Dysplasia
Dr. Rita Ann Kubicky
Pediatric Endocrinology
160 E Erie Ave, 
Philadelphia, PA 
 (5.5 miles away)
215-427-5000
Languages Spoken:
English
See accepted insurances

Rita Ann Kubicky is a Pediatric Endocrinologist in Philadelphia, Pennsylvania. Dr. Ann Kubicky is rated as an Advanced provider by MediFind in the treatment of Septo-Optic Dysplasia. Her top areas of expertise are Type A Insulin Resistance Syndrome, Acanthosis Nigricans, Pseudohypoparathyroidism, and Albright's Hereditary Osteodystrophy.

Advanced in Septo-Optic Dysplasia
Dr. Daniel Doyle
Pediatric Endocrinology
Advanced in Septo-Optic Dysplasia
Dr. Daniel Doyle
Pediatric Endocrinology
A.i. Dupont Hospital For Children, 1600 Rockland Road, 
Wilmington, DE 
 (21.1 miles away)
302-651-4000
Languages Spoken:
English
See accepted insurances

Daniel Doyle is a Pediatric Endocrinologist in Wilmington, Delaware. Dr. Doyle is rated as an Advanced provider by MediFind in the treatment of Septo-Optic Dysplasia. His top areas of expertise are Idiopathic Short Stature (ISS), Familial Short Stature (FSS), Short Stature (Growth Disorders), and Hypogonadotropic Hypogonadism.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Willi's expertise for a condition
ConditionClose
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile